down arrow

VolitionRX Ltd.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US9286611077
USD
0.31
0.03 (9.49%)

Dec 04

ASE

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.280.32

52 Week

0.270.94
Valuation
Technical
Day's Volume

CASH

2.4 M

Shareholding (Mar 2025)

FII

0.06%

Held by 7 FIIs

DII

98.26%

Held by 4 DIIs

Promoter

0.00%

How big is VolitionRX Ltd.?

22-Jun-2025

As of Jun 18, VolitionRX Ltd. has a market capitalization of 67.17 million and reported net sales of 1.31 million, with a net loss of 24.27 million over the last four quarters. The company's balance sheet shows shareholder's funds of -24.91 million and total assets of 9.40 million.

As of Jun 18, VolitionRX Ltd. has a market capitalization of 67.17 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 1.31 million for the latest four quarters. During the same period, the net profit was a loss of 24.27 million.<BR><BR>As of Dec 24, the company's balance sheet shows shareholder's funds of -24.91 million and total assets amounting to 9.40 million.

Read More

What does VolitionRX Ltd. do?

22-Jun-2025

VolitionRX Ltd. is a clinical-stage life sciences company developing blood-based diagnostic tests for cancer and other diseases, with a market cap of $67.17 million and recent net sales of $0 million. As of March 2025, it reported a net loss of $5 million.

Overview: <BR>VolitionRX Ltd. is a clinical-stage life sciences company focused on developing blood-based diagnostic tests for detecting and diagnosing cancer and other diseases, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -5 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 67.17 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.15 <BR>Return on Equity: 87.60% <BR>Price to Book: -2.42<BR><BR>Contact Details: <BR>Address: Galleria Oaks B, AUSTIN TX: 78738-6439 <BR>Tel: 1 646 6501351 <BR>Fax: 65 6 3337235 <BR>Website: https://www.volitionrx.com/

Read More

Who are in the management team of VolitionRX Ltd.?

22-Jun-2025

As of March 2022, the management team of VolitionRX Ltd. includes Dr. Martin Faulkes (Executive Chairman), Mr. Cameron Reynolds (President and CEO), and several independent directors: Dr. Phillip Barnes, Dr. Salvatore Butera, Dr. Alan Colman, Dr. Edward Futcher, and Mr. Guy Innes. This team provides governance and strategic direction for the company.

As of March 2022, the management team of VolitionRX Ltd. includes the following individuals:<BR><BR>- Dr. Martin Faulkes, who serves as the Executive Chairman of the Board.<BR>- Mr. Cameron Reynolds, who is the President, Chief Executive Officer, and a Director.<BR>- Dr. Phillip Barnes, who is an Independent Director.<BR>- Dr. Salvatore Butera, who is also an Independent Director.<BR>- Dr. Alan Colman, serving as an Independent Director.<BR>- Dr. Edward Futcher, who is an Independent Director.<BR>- Mr. Guy Innes, who is an Independent Director.<BR><BR>This team comprises a mix of executive leadership and independent directors, contributing to the governance and strategic direction of the company.

Read More

Is VolitionRX Ltd. overvalued or undervalued?

20-Sep-2025

As of November 14, 2024, VolitionRX Ltd. is rated as risky due to significant overvaluation indicated by negative valuation ratios and a poor 3-year return of -62.40%, underperforming the S&P 500's 70.41%.

As of 14 November 2024, the valuation grade for VolitionRX Ltd. has moved from does not qualify to risky, indicating a significant deterioration in its investment profile. The company appears to be overvalued, given its negative valuation ratios, including a Price to Book Value of -2.06 and an EV to EBITDA of -2.67, which suggest that the market is pricing the stock unfavorably compared to its fundamental value. Additionally, the EV to Sales ratio stands at 46.73, further highlighting the company's overvaluation relative to its revenue generation.<BR><BR>In comparison to its peers, VolitionRX Ltd. has a less favorable EV to EBITDA ratio than Perspective Therapeutics, Inc. at -0.7951 and Prenetics Global Ltd. at -1.5438, both of which also fall into the risky category. Notably, VolitionRX has underperformed against the S&P 500, with a 3-year return of -62.40% compared to the index's 70.41%, reinforcing the notion that the stock is struggling in the current market environment.

Read More

Is VolitionRX Ltd. technically bullish or bearish?

20-Sep-2025

As of September 12, 2025, VolitionRX Ltd. shows a mildly bullish trend with mixed technical indicators, having underperformed the S&P 500 significantly over the past year and five years, suggesting caution despite some positive momentum.

As of 12 September 2025, the technical trend for VolitionRX Ltd. has changed from sideways to mildly bullish. The daily moving averages indicate a mildly bullish stance, while the weekly MACD and KST are mildly bearish, creating a mixed signal overall. The monthly MACD and KST, however, are mildly bullish, suggesting some positive momentum over a longer timeframe. The Bollinger Bands and Dow Theory indicate bearish conditions on the weekly and monthly charts, which adds to the uncertainty.<BR><BR>In terms of performance, VolitionRX has underperformed compared to the S&P 500 across multiple periods, with a 1-year return of 1.61% versus 17.14% for the S&P 500, and a significant decline of 79.93% over the past 5 years compared to a 96.61% gain in the index. Overall, the current technical stance is mildly bullish, but the mixed indicators suggest caution.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 66 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.25

stock-summary
Return on Equity

75.11%

stock-summary
Price to Book

-2.07

Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Jun 2025)
Net Profit:
-6 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-50.95%
0%
-50.95%
6 Months
-45.41%
0%
-45.41%
1 Year
-45.18%
0%
-45.18%
2 Years
-56.28%
0%
-56.28%
3 Years
-86.1%
0%
-86.1%
4 Years
-90.02%
0%
-90.02%
5 Years
-91.03%
0%
-91.03%

VolitionRX Ltd. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is VolitionRX Ltd. technically bullish or bearish?

As of 12 September 2025, the technical trend for VolitionRX Ltd. has changed from sideways to mildly bullish. The daily moving averages indicate a mildly bullish stance, while the weekly MACD and KST are mildly bearish, creating a mixed signal overall. The monthly MACD and KST, however, are mildly bullish, suggesting some positive momentum over a longer timeframe. The Bollinger Bands and Dow Theory indicate bearish conditions on the weekly and monthly charts, which adds to the uncertainty. In terms of performance, VolitionRX has underperformed compared to the S&P 500 across multiple periods, with a 1-year return of 1.61% versus 17.14% for the S&P 500, and a significant decline of 79.93% over the past 5 years compared to a 96.61% gain in the index. Overall, the current technical stance is mildly bullish, but the mixed indicators suggest caution....

Read More

Is VolitionRX Ltd. overvalued or undervalued?

As of 14 November 2024, the valuation grade for VolitionRX Ltd. has moved from does not qualify to risky, indicating a significant deterioration in its investment profile. The company appears to be overvalued, given its negative valuation ratios, including a Price to Book Value of -2.06 and an EV to EBITDA of -2.67, which suggest that the market is pricing the stock unfavorably compared to its fundamental value. Additionally, the EV to Sales ratio stands at 46.73, further highlighting the company's overvaluation relative to its revenue generation. In comparison to its peers, VolitionRX Ltd. has a less favorable EV to EBITDA ratio than Perspective Therapeutics, Inc. at -0.7951 and Prenetics Global Ltd. at -1.5438, both of which also fall into the risky category. Notably, VolitionRX has underperformed against the S&P 500, with a 3-year return of -62.40% compared to the index's 70.41%, reinforcing the notion ...

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
18.13%
EBIT Growth (5y)
-5.24%
EBIT to Interest (avg)
-28.80
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.15
Sales to Capital Employed (avg)
0.00
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
22.50%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-2.06
EV to EBIT
-2.53
EV to EBITDA
-2.67
EV to Capital Employed
-2.58
EV to Sales
46.73
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 5 Schemes (1.68%)

Foreign Institutions

Held by 7 Foreign Institutions (0.06%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 100.00% vs 0.00% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -14.55% vs 6.78% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.40",
          "val2": "0.20",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-6.00",
          "val2": "-5.20",
          "chgp": "-15.38%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.40",
          "val2": "0.10",
          "chgp": "300.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.40",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-6.30",
          "val2": "-5.50",
          "chgp": "-14.55%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-15,485.60%",
          "val2": "-22,410.90%",
          "chgp": "692.53%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 50.00% vs 166.67% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 23.53% vs -16.67% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1.20",
          "val2": "0.80",
          "chgp": "50.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-25.70",
          "val2": "-34.60",
          "chgp": "25.72%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.30",
          "val2": "0.20",
          "chgp": "50.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.20",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-27.30",
          "val2": "-35.70",
          "chgp": "23.53%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-21,909.00%",
          "val2": "-46,417.60%",
          "chgp": "2,450.86%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.40
0.20
100.00%
Operating Profit (PBDIT) excl Other Income
-6.00
-5.20
-15.38%
Interest
0.40
0.10
300.00%
Exceptional Items
0.40
0.00
Consolidate Net Profit
-6.30
-5.50
-14.55%
Operating Profit Margin (Excl OI)
-15,485.60%
-22,410.90%
692.53%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 100.00% vs 0.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -14.55% vs 6.78% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
1.20
0.80
50.00%
Operating Profit (PBDIT) excl Other Income
-25.70
-34.60
25.72%
Interest
0.30
0.20
50.00%
Exceptional Items
0.00
0.20
-100.00%
Consolidate Net Profit
-27.30
-35.70
23.53%
Operating Profit Margin (Excl OI)
-21,909.00%
-46,417.60%
2,450.86%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 50.00% vs 166.67% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 23.53% vs -16.67% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About VolitionRX Ltd. stock-summary
stock-summary
VolitionRX Ltd.
Pharmaceuticals & Biotechnology
VolitionRx Limited is a clinical-stage life sciences company. The Company is focused on developing blood-based diagnostic tests for detecting and diagnosing cancer and other diseases. The Company has developed approximately 30 blood-based assays to detect specific biomarkers that can be used individually or in combination to generate a profile, which forms the basis of a test for a particular cancer or disease. The Company's Nucleosomics biomarker platform is a technology that is used for a range of cancers. The Company is developing Nucleosomics tests for various cancers, including colorectal, pancreatic, lung and aggressive prostate. The Company's NuQ blood assays fall into over five types, which include NuQ-X, NuQ-V, NuQ-M, NuQ-A and NuQ-T. It has developed approximately two blood assays in the NuQ-X family to detect the presence of cancer by detecting nucleosomes containing specific nucleotides.
Company Coordinates stock-summary
Company Details
Galleria Oaks B , AUSTIN TX : 78738-6439
stock-summary
Tel: 1 646 65013511 646 6501351
stock-summary
https://www.volitionrx.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."